Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Estimated Cystic Fibrosis patient population in U.S. by Year
Estimated Cystic Fibrosis (CF) patient population in U.S., Europe, Australia & Canada (patients)
Vertex Pharmaceuticals Estimated Cystic Fibrosis patient population in U.S.: 97,000.00 patients in FY2025, up 3.2% from a year earlier. That is the highest of the 11 years on record here.
Where the FY2025 figure comes from
“Our marketed CF medicines, ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) , TRIKAFTA/KAFTRIO (elexacaftor/ tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ ivacaftor) and KALYDECO (ivacaftor) , are being used by nearly three quarters of the approximately 97,000 people with CF in the U.S., Europe, Australia, and Canada.”
Source: Form 10-K (vrtx-20251231.htm, filed 2026-02-13) ↗
Reported in Form 10-K Item 1 (Business — Cystic Fibrosis Disease & Market Overview).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Vertex Pharmaceuticals Estimated Cystic Fibrosis patient population in U.S., annual FY2015–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/cf-patient-pop-core
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.